Median progression-free survival was 7.6 months with the combination versus 5.4 with chemotherapy; results were presented at ...
Study patients had high-grade serous, platinum-resistant ovarian cancer and a median of four prior lines of therapy. Call ...
Share-transfer books are expected to close Nov. 5. Elme plans to move remaining assets to a trust; the trustee sets the ...
Among 459 participants, more with blood in urine saw it resolve on sefaxersen than placebo; blinded follow-up will measure ...
KRAS mutations affect about 40% of colorectal cancers, and G12D is the most common. Genmab will conduct the study; Incyte ...
The 56% response rate came from 25 patients with CEA-high tumors; BeOne intends to advance both lung programs toward ...
PRAME-high melanoma: 12.5-month median response duration; 91% alive at one year. First data on IMA402 with IMA401 in lung cancer are expected in 2027.
At week 12, 60% of patients without prior advanced therapy failure had an endoscopic response, versus 15% on placebo; ...
The analysis included 295 people and found reductions in all four urinary markers, adding evidence FILSPARI may affect ...
SUNS declared a prorated $0.09-per-share fourth-quarter dividend, payable Nov. 5 to holders of record Nov. 2; the merger ...
MakerSpace used 3D scans to give other manufacturers precise measurements for custom parts; auction proceeds will benefit The ...
The 10:30 a.m. Eastern call will cover results for the six months ended June 30, operations and Q&A; the presentation deck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results